NADPH oxidase (NOX)-derived reactive oxygen species (ROS) have been demonstrated to mediate the activation of NOD-like receptor protein 3 (NLRP3) inflammasomes in podocytes in response to elevated levels of homocysteine (Hcys). However, it remains unknown how NLRP3 inflammasome activation is triggered by NOX. The present study tested whether the guanine nucleotide exchange factor Vav2 mediates Rac1-mediated NOX activation in response to elevated Hcys leading to NLRP3 inflammasome activation in podocytes and consequent glomerular injury. In a mouse model of hyperhomocysteinemia (hHcys), we found that mice with hHcys (on the FF diet) or oncoVav2 (a constitutively active form of Vav2) transfection in the kidney exhibited increased colocalization of NLRP3 with apoptosis-associated speck-like protein (ASC) or caspase-1 and elevated IL-1β levels in glomeruli, indicating the formation and activation of the NLRP3 inflammasome. This glomerular NLRP3 inflammasome activation was accompanied by podocyte dysfunction and glomerular injury, even sclerosis. Local transfection of Vav2 shRNA plasmids significantly attenuated hHcys-induced NLRP3 inflammasome activation, podocyte injury, and glomerular sclerosis. In cultured podocytes, Hcys treatment and oncoVav2 transfection were also found to increase NLRP3 inflammasome formation and activation, which were all inhibited by Vav2 shRNA. Furthermore, Vav2 shRNA prevented Hcys-induced podocyte damage as shown by restoring Hcys-impaired VEGF secretion and podocin production. This inhibitory action of Vav2 shRNA on Hcysinduced podocyte injury was associated with reduction of Rac1 activity and ROS production. These results suggest that elevated Hcys levels activate Vav2 and thereby increase NOX activity leading to ROS production, which triggers NLRP3 inflammasome activation, podocyte dysfunction and glomerular injury.
Introduction
Hyperhomocysteinemia (hHcys) has been identified as one of the leading pathogenic factors in the progression of end-stage renal disease (ESRD) and is associated with an increased risk for cardiovascular complications. Amongst the growing prevalence of chronic kidney disease, hHcys is a prevalent comorbidity occurring in 85% of diagnosed ESRD patients [1] . The early mechanisms responsible for the pathogenic action of increased Hcys levels during ESRD or other kidney-associated diseases still remain unclear. Prior studies have demonstrated that a reduction in glomerular filtration rate (GFR) contributes to the increases in both serum creatinine and Hcys [2] [3] [4] . Elevated concentrations of Hcys leads to endothelial damage and dysfunction that progresses into a buildup of extracellular matrix proteins, ultimately inducing renal glomerular sclerosis and atherosclerosis [5] [6] [7] . The pathogenic role of elevated plasma Hcys has been attributed to its direct action on cells or organs and to effects of its metabolites. For example, Hcys has been reported to act on the NMDA receptor to activate NADPH oxidase (NOX) producing local oxidative stress and thereby leading to tissue damage such as glomerular injury. Hcys can also be transported into the cells to induce endoplasmic reticulum stress, homocysteinylation, and hypomethylation leading to cell dysfunction [8, 9] . Increases in tissue Hcys levels have also been shown to reduce the production of adenosine which has potential protective effects in many tissues or organs upon different pathogenic challenges [9] . In addition, there is evidence that Hcys can be converted into homocysteine-thiolactone and homocystamides promoting freeradical production and oxidative damage to proteins [10] . With respect to the role of hHcys in chronic degenerative disease, Hcys-induced tissue oxidative stress through different pathways and consequent derangement of extracellular matrix metabolism are considered to be critical [11, 12] . In the kidney, hHcys has been reported to result in glomerular degenerative diseases mainly through podocyte dysfunction and injury similar to other metabolic disorders such as diabetes mellitus, where glomerular pathological modifications will develop even though the initiating pathogenic factors have been removed or disappear. Understanding the mechanisms leading to hHcys-induced podocyte injury may facilitate new approaches to treatment of patients with hHcys-associated ESRD.
Recent studies have reported that hHcys leads to inflammasome activation which is responsible for glomerular injury and ultimately leads to sclerosis [13] [14] [15] . The inflammasome is a multiprotein complex recognized as an intracellular machinery for activation of inflammatory responses and diseases [16] . One of the most important inflammasome isoforms is the NLRP3 inflammasome comprised of NOD-like receptor protein 3 (NLRP3), an adaptor protein called apoptosis-associated speck-like protein (ASC), and caspase-1 [16] . Detection of non-microbial reactive oxygen species (ROS), ATP, hypotonic stress, uric acid crystals, asbestos and UV radiation as well as invading pathogens, the formation and activation of the NLRP3 inflammasome are triggered, resulting in autocatalytic activation of caspase-1 and subsequent cleavage of pro-IL-1β and pro-IL-18 into their mature forms [16] . This NLRP3 inflammasome activation has been implicated in the pathogenesis of various metabolic diseases including diabetes, gout, silicosis, acute myocardial infarction and liver toxicity [17] [18] [19] [20] [21] . Our laboratory has recently demonstrated that increased Hcys around podocytes induces NLRP3 inflammasome activation, which contributes to glomerular injury and sclerosis during hHcys [15] . Moreover, we have shown that NADPH oxidase (NOX)-derived ROS mediates the activation of the NLRP3 inflammasome [13, 14] , leading to glomerular injury and sclerosis [11] . Inhibition of NOX by different strategies resulted in protection from glomerular dysfunction and injury as seen by decreased urinary protein excretion, improved glomerular damage and increased matrix metalloproteinase-1 activity [12] . However, it remains unknown how NOX is activated by increased Hcys and consequently results in NLRP3 inflammasome formation in podocytes to produce glomerular injury and sclerosis.
There is evidence that NOX is comprised of membrane-bound subunits gp91 phox and p22 phox as well as cytosolic subunits p47 phox , p40 phox , and p67 phox [22] . The major regulatory step necessary for activation of NOX involves heterodimerization of gp91 phox and p67 phox mediated by the Rac protein. Conversion of GDP-bound Rac to activated GTP-bound Rac via a guanine nucleotide exchange factor (GNEF) initiates the translocation of the cytosolic subunit to the membrane [23, 24] . It has been reported that the Vav subfamily represents distinct GNEFs with high specificity to Rac-mediated NOX activation [25] [26] [27] . It is possible that the activation of Vav2 through elevated Hcys accelerates the switch from GDP to GTP, thereby enhancing NOX activity and O 2 .-production, which may instigate the cascade to glomerular sclerosis by activation of the NLRP3 inflammasomes in podocytes. The present study was designed to test this hypothesis. During our experiments, we first used a hyperhomocysteinemic mouse model to test the effects of overexpression or inhibition of Vav2 on NLRP3 inflammasome formation and activation as well as on glomerular injury induced by hHcys. Then, we went on to explore the molecular mechanisms by which Hcys results in NLRP3 inflammasome activation and podocyte dysfunction or injury. 2. Materials and methods
Animals
Eight weeks old mice on a C57BL/6J background were purchased from Jackson Laboratories (Bar Harbor, ME). All protocols were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. To produce a rapid and advanced model of hHcys, mice were uninephrectomized and afterward allowed 1-week to recover. Short hairpin RNA (shRNA)-Vav2 or a dominantactive Vav2 variant (oncoVav2) plasmids with a luciferase expression vector were co-transfected into the kidneys via an intrarenal artery injection using the ultrasound-microbubble system. Plasmids containing scrambled small RNA (sRNA) were used as a control. After introduction of plasmids into the kidney, these uninephrectomized mice were fed either a normal diet (ND) or a folate-free (FF) diet to induce hHcys (Dyets Inc, Bethlehem, PA). One day before sacrifice, 24-h urine samples were collected using mouse metabolic cages and afterward blood samples were collected. The mice were sacrificed and renal tissues were harvested for biochemical and molecular analysis as well as for morphological examinations.
Cell culture
A conditionally immortalized mouse podocyte cell line gifted by Dr. Paul E. Klotman (Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA) was cultured undifferentiated with 10 U/mL recombinant mouse interferon-γ at 33°C on collagen I-coated flasks in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin. Prior to experiments, podocytes were thermoshifted at 37°C for 10-14 days to differentiate in the absence of interferon-γ and afterwards treated with 40 μM of L-Hcys for 24 h.
RNAi
Podocytes were transfected with scrambled sRNA, Vav2 shRNA or constitutively active form of Vav2 (oncoVav2) plasmids directly into the nucleus via 4D-Nucleofector Technology (Lonza, Basel, Switerland). Small pores in the cell membrane develop temporarily through electrical impulses and cell-specific solutions. Substrates are then delivered through the cytoplasm and into the nuclear membrane. 2×10 6 podocytes were resuspended in SF Cell Line nucleofector solution containing 2 μg plasmid DNA, subject to cell-type specific program CM-137, and transferred to cultured plates. An additional group of podocytes was transfected using the siLentFect Lipid Reagent (Bio Rad, Berkeley, CA) incubated in serum-free medium with siRNA for 25 min according to the manufacturer's instructions.
Confocal microscopy
Frozen tissue sections or podocytes seeded in 8-well chambers were used to detect the expression and colocalization of NLRP3 (Abcam, Cambridge, MA), ASC (Santa Cruz, Santa Cruz, CA), caspase-1 (Santa Cruz, Santa Cruz, CA), podocin (Santa Cruz, Santa Cruz, CA) and desmin (BD Biosciences, San Jose, CA) in glomeruli and podocytes, where Alexa-488-conjugated secondary antibody was used to label NLRP3 and Alex-555 was used to label ASC, caspase-1, podocin and desmin. In addition, gene transfection efficiency in mouse glomeruli was determined by measuring Vav2 (Santa Cruz, Santa Cruz, CA) expression levels in frozen kidney sections.
Immunohistochemical staining
Kidneys were perfused in 4% paraformaldehyde, removed and fixed in 10% neutral buffered formalin. 5-μm tissue sections embedded in paraffin were cut and mounted onto microscope slides. Deparaffinization was induced through heat, tissue cleaning agent, ethanol and water. To unmask antigen binding sites, slides were boiled in 0.01 M citrate buffer pH 6.0 for 20 min. Endogenous peroxidase activity was blocked by incubating slides in 3% H 2 O 2 in 100% MeOH for 30 min. The sections were then incubated at room temperature for 30 min in 10% goat serum to block nonspecific binding and incubated overnight at 4°C in a humidified chamber with antibodies against IL-1β (Abcam, Cambridge, MA) diluted 1:50 in TBS-T containing 4% goat serum. Then, the slides were incubated for 30 min at room temperature in a humidified chamber with a biotinylated goat anti-rabbit IgG-B antibody diluted 1:200 in TBS-T. The slides were subsequently placed in streptavidin-horseradish peroxidase for 30 min at room temperature in a humidified chamber. Finally, the slides were incubated with 50 μL of diaminobenzidine (BioGenex, San Ramon, CA) as a substrate, counterstained with hematoxylin (Sigma-Aldrich, Saint Louis, MO), dehydrated, and fixed with Permount histological mounting medium (Fisher Scientific, Hampton, NH).
Caspase-1 activity, urinary protein measurements, IL-1β and VEGF
Caspase-1 activity (Biovision, Mountain View, CA) was measured by a commercially available colorimetric assay kit. ELISA kits were used for quantitation of urinary albumin (Bethyl Laboratories Inc., Montgomery, TX), IL-1β production (R & D Systems, Minneapolis, MN) and VEGF (Bender Med Systems, San Diego, CA). All assays were performed according to the manufacturer's instructions. 
Morphological examinations
Glomerular structure was examined using fixed paraffin-embedded kidneys, stained with a Periodic-Acid Schiff (PAS) stain. Glomeruli were scored on a scale of 0-4 depending on the extent of sclerotic changes. In general, 30-50 glomeruli were counted under the microscope, 0 represents no lesion, 1 represents sclerosis < 25% of the glomerulus while 2, 3 and 4 represent sclerosis at 25-50%, > 50% to 75%, and > 75% of the glomerulus, respectively. A general glomerular damage index (GDI) was obtained by averaging scores from counted glomeruli. This observation was examined by at least 3 investigators and averaged under blind conditions.
Assay of Rac-1 activation
A GTPase linked immunosorbent assay was performed to determine Rac-1 activation in vitro using a colorimetric based assay kit (Cytoskeleton, Denver, CO). Podocytes were lysed in provided lysis buffer and clarified to remove cellular debris by centrifugation at 10,000×g for 1 min at 4°C. Equal amounts of protein (1 mg/mL) were loaded onto a Rac-1 GTP affinity plate for 30 min. Following incubation, the plate was washed with wash buffer, then incubated with a primary antibody against Rac-1 and then with a secondary antibody labeled with Horseradish Peroxidase (HRP). The activated Rac-1 was determined after exposure to HRP detection reagents by measuring absorbance at 490 nm using a microplate spectrophotometer. production or its level, which were shown as the fold changes of control.
Results

In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome formation and activation
Using a hyperhomocysteinemic mouse model, we tested whether Vav2 facilitates hHcys-induced inflammasome formation and glomeru- lar injury. By confocal microscopy, we found that hHcys and oncoVav2 transfected mice fed a normal or folate-free (FF) diet exhibited increased colocalization of NLRP3 with ASC and NLRP3 with caspase-1 (Fig. 1) . However, this colocalization was inhibited in mice transfected with Vav2 shRNA (Fig. 1) . The summarized data is shown in Fig. 1C and D. Since activation of the NLRP3 inflammasome is associated with the maturation of the pro-inflammatory cytokine, IL-1β, we measured the IL-1β levels in mouse glomeruli using immunohistochemistry. We detected a significant increase in IL-1β levels in hHcys mice and mice receiving the oncoVav2 plasmids on both normal and FF diets ( Fig. 2A) . However, blockade of Vav2 abolished further increases in hHcys-induced glomerular IL-1β ( Fig. 2A) . This data indicates that Vav2 is involved in both assembling and activation of the NLRP3 inflammasome in glomeruli of mice with hHcys, which could be mimicked by overexpression of Vav2.
Glomerular protection by Vav2 inhibition
It is well recognized that protein in the urine is a hallmark of many glomerular diseases. After a 24-h urine collection, protein and albumin levels were evaluated in collected mouse urine to serve as an indicator of glomerular injury. As illustrated in Fig. 3A and B, the FF diet produced both proteinuria and albuminuria in scramble sRNA-transfected mice, and the increased urinary excretion of protein and albumin was also observed in oncoVav2 transfected mice on a normal diet (ND), but albumin excretion in mice with oncoVav2 transfection and FF diet consumption was similar to mice on the ND. However, this increased albuminuria induced by the FF diet or oncoVav2 alone was attenuated in mice receiving intrarenal Vav2 shRNA transfection (Fig. 3A and B) .
Furthermore, this glomerular dysfunction was correlated to modifications in the glomerular architecture as shown by morphological examinations. It was found that scramble sRNA and oncoVav2 plasmid-transfected mice fed a FF diet developed increased sclerotic damage to their glomeruli, as shown by mesangial expansion, fibrosis and hypercellularity with an increased glomerular damage index (GDI) (Fig. 3C and D) . Inhibition of Vav2 by shRNA protected mice from this glomerular sclerotic pathology. Immunofluorescence analysis demonstrated that the expression of podocin decreased in oncoVav2 transfected mice on either the ND or the FF diet, but this decrease in podocin levels was not seen in Vav2 shRNA transfected mice on the same diet (Fig. 4A) . In contrast, the levels of desmin, a marker of podocyte injury, increased in oncoVav2 transfected mice, but not in Vav2 shRNA transfected mice (Fig. 4B) . Furthermore, as shown in Fig. 4C , Vav2 protein levels were significantly lower in scramble sRNA and Vav2 shRNA transfected mice, as depicted by green staining. Fig. 4D showed the relative intensity of Vav2 staining in oncoVav2 transfected mice, which exhibited a two-fold increase in comparison to that seen in scramble sRNA transfected mice.
Role of Vav2 in Hcys-induced NLRP3 inflammasome formation in podocytes
The glomerulus is comprised of specialized cells that operate in a partnership to preserve the integrity of the kidney. Evidence strongly links podocyte injury to the pathogenesis of many glomerular diseases [28, 29] . To better understand the impact of glomerular dysfunction during hHcys, we chose to further investigate the molecular mechanisms initiating injury in podocytes by employing cultured podocytes. 
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Our initial studies determined if Vav2 is involved in Hcys-induced inflammasome formation in these cells. By confocal microscopic analysis, we detected increased colocalization of NLRP3 with ASC or caspase-1 in Hcys-treated podocytes when compared with untreated cells (Fig. 5) . However, this Hcys-induced increase in colocalization was inhibited in podocytes transfected with Vav2 shRNA (Fig. 5) . Additionally, oncoVav2 overexpression increased colocalization of inflammasome molecules in both control and Hcys-treated groups of podocytes. The quantitative colocalization of NLRP3 with ASC or caspase-1 is summarized in Fig. 5C and D.
Activation of the NLRP3 inflammasome in vitro
We confirmed the role of Vav2 in Hcys-induced inflammasome activation by measuring the levels of active or cleaved caspase-1 and the level of secreted IL-1β. As shown in Fig. 6 , Hcys treatment increased caspase-1 activity and IL-1β production in comparison to control podocytes. Hcys-induced increase in caspase-1 activity and elevation in IL-1β levels were significantly attenuated in podocytes transfected with Vav2 shRNA (Fig. 6) . Transfection with oncoVav2 mimicked the effects of Hcys which increased caspase-1 activity and elevated IL-1β levels in cultured podocytes (Fig. 6) .
Inhibition of Vav2 improved podocytes damage
We further assessed the participation of Vav2 in podocyte dysfunction induced by Hcys. It was found that upon stimulation with Hcys, there was decreased staining of the podocyte marker podocin in Hcystreated and oncoVav2-transfected podocytes, whereas desmin levels increased in these groups, suggesting damage to podocytes (Fig. 7A) . However, Vav2 shRNA reversed Hcys-induced podocyte damage (Fig. 7A) . Additionally, we observed that Hcys treatment and oncoVav2 transfection resulted in significant impairment of podocytes to secrete vascular endothelial growth factor (VEGF), a major product of healthy and mature podocytes (Fig. 7B) . Inhibition of Vav2 protected podocytes from such injury or dysfunction, which was seen by restored levels of VEGF secretion (Fig. 7B ).
Effects of Rac-1 activation on Hcys-induced NOX activity
It is well-defined that activated Rac serves as an anchor protein to regulate NOX activity in many cell types [30] [31] [32] . We have shown that Hcys treatment and oncoVav2 transfection resulted in increased Rac-1 activation in cultured podocytes (Fig. 8A) . A significant decrease in Rac-1 activity was observed in podocytes with silenced Vav2 gene, suggesting that more Rac-1 remains in the GDP-bound or inactive state (Fig. 8A) . Coupled with increased GTP-bound Rac-1, we also found that oncoVav2 transfection produced a great increase in O 2 .-, which was inhibited in the Vav2 shRNA transfected podocytes (Fig. 8B) . 
Discussion
The primary goal of this study was to reveal the involvement of the GNEF, Vav2 in activation of the NLRP3 inflammasome during hHcys. Our results showed that Vav2 inhibition by RNA interference attenuated hHcys-induced NLRP3 inflammasome formation and activation in podocytes. Conversely, overexpression of Vav2 resulted in enhanced inflammasome formation and activation in these cells independent of Hcys treatment. Results from the present study also demonstrated that Vav2 inhibition protected podocytes against Hcys-induced glomerular injury. This Vav2-mediated action was associated with NOX activation and increased ROS production in glomeruli.
Distinctive GNEFs facilitate the conversion of GDP for GTP, inciting Rho protein activation [33] . Among more than 100 GNEFs, the Vav subfamily is highly selective in coordinating intracellular signal transduction pathways associated with NOX activation [34, 35] . Our earlier studies have demonstrated that of the 3 Vav isoforms, both Vav2 and Vav3 are localized in the glomeruli, whereas it is already established in other reports that Vav1 is solely present in hematopoietic cells [26] . We 
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have shown that by sensing intracellular ROS during hHcys, thioredoxin-interacting protein (TXNIP) associates with NLRP3 to trigger the cascade of downstream events leading to inflammasome activation [36] . Recently, evidence links Vav2 as a binding partner of TXNIP [37] . Therefore, we sought to identify whether the detrimental actions of Vav2 is involved in NLRP3 inflammasome assembling, activation and subsequent podocyte dysfunction. It has been reported that internal or external danger signals are capable of initiating the recruitment of ASC and caspase-1, forming the NLRP3 inflammasome complex [16, 38] . This inflammasome complex triggers the production of IL-1β and IL-18, inducing a heightened inflammatory response. Processing of not only the interleukins, but also caspase-1 is considered crucial in the inflammatory process that leads to tissue injury, organ or systemic diseases [39] . In particular, NLRP3 inflammasome activation has been implicated in the pathogenesis of various renal diseases including acute kidney injury, chronic kidney disease, diabetic nephropathy, crystal related nephropathy and hyperhomocysteinemic nephropathy [17, 40, 41] . Renal cells such as podocytes have been documented as the main enriched sites for maturation of glomerular IL-1β production [13, 15] . To our knowledge, we are the first to report that silencing the Vav2 gene and reduction of its activity using genetic manipulations inhibited the NLRP3 inflammasome by preventing the activation of the small G TPase, Rac-1. Consistent in both our in vivo and in vitro models, our results show that Vav2 shRNA interventions decreased the interactions of inflammasome components NLRP3, ASC and caspase-1 ( Figs. 1 and  5) . Consequently, the absence of inflammasome machinery resulted in decreased IL-1β production in mouse glomeruli (Fig. 2 ) which was associated with diminished caspase-1 activity in podocytes (Fig. 7) . The most remarkable finding in the present study was that Vav2 overexpression triggered NLRP3 inflammasome formation irrespective of Hcys exposure (Figs. 1 and 5 ), suggesting that Vav2 is crucial in bridging the redox signals derived from NOX activity and NLRP3 inflammasome activation, which may be a critical mechanism responsible for glomerular inflammatory response during hHcys.
There is evidence that abundance of protein leaked in the urine and excessive reabsorption of protein in renal proximal tubular cells are linked to the pathophysiological states of renal disease development [42, 43] . In this regard, Connell et al. demonstrated that in response to albumin overloads, proximal tubule cells encounter direct toxic effects associated with Rac GTPase and NOX activation as well as receptormediated endocytosis [44] . Our results add to this by showing that mice with overexpressed Vav2 had typical features of glomerular damage as evidenced by proteinuria, albuminuria and increased GDI (Fig. 3) . Downregulation of the Vav2 gene effectively ameliorated these detrimental effects in mouse glomeruli. With respect to the mechanism of glomerular injury during different pathological conditions such as hHcys, podocyte injury is considered to play an important role. It has been reported that disruption of the slit diaphragm, actin rearrangement and foot process effacement are unique indicators of podocyte injury [28, 45] . Our data revealed that Hcys treatment and Vav2 overexpression decreased a podocyte-specific molecule, podocin (Figs. 4 and 7) , which may result in derangement of the slit diaphragm structure and related cell signaling pathways [45] . Furthermore, resultant injury to podocytes may lead to the upregulation of the intermediate filament, desmin, which was indeed confirmed in our studies as shown by increased desmin levels in podocytes during hHcys or exposure to high levels of extracellular Hcys. Interestingly, this desmin increase in podocytes during hHcys could be blocked by shRNA of Vav2, but mimicked by oncoVav2 transfection. The results suggest that Vav2 critically contributes to hHcys-induced podocyte injury and glomerular sclerosis.
To explore the mechanism by which Vav2 activates the NLRP3 inflammasome and thereby lead to podocyte injury and glomerular sclerosis, we examined the effects of Vav2 interventions on Rac activity and consequent NOX activation. It is well known that instigation of NOX as a functional signaling complex is dependent on the translocation of its cytosolic subunits (p47 phox and p67 phox ) to the membrane in which this platform initiates the generation of superoxide (O 2 .-) [22, 46] . The Rac protein is crucial in these migratory events, serving as a binary switch that cycles between active GTP-bound and inactive GDP-bound states. However, the molecular cues directly responsible for Rac protein activation and subsequent NOX activity following prolonged exposure to Hcys remained unclear. From our findings, we confirmed that expression of constitutively active Vav2, can itself drive the activation of the Rac-1 protein (Fig. 8A ) and the aggregation of a functional NOX complex, which produces O 2 .-even without Hcys stimulus (Fig. 8B) Altogether, the results from the present study signify that Vav2 is critically involved in Hcys-induced NLRP3 inflammasome formation and activation, which may critically contribute to podocyte dysfunction and glomerular injury. These results also demonstrate that Rac-1-NOX activation and subsequent production of O 2 .-are major triggering mechanisms of the NLRP3 inflammasome in podocytes, which is consistent with previous reports [14, 36] . Vav2 may be a therapeutic target for termination of early events in hyperhomocysteinemic nephropathy and ESRD.
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